预约演示
更新于：2025-06-25
Bimatoprost
贝美前列素
更新于：2025-06-25
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H37NO4 |
InChIKeyAQOKCDNYWBIDND-FTOWTWDKSA-N |
CAS号155206-00-1 |
关联
150
项与 贝美前列素 相关的临床试验IRCT20190210042676N36
Evaluation of safety and efficacy profile of the eyelash booster solution containing stemoxydine and bimatoprost on women with hypotrichosis
CTIS2023-504759-28-00
RANDOMIZED, OPEN LABEL, PARALLEL-GROUP, TWO-ARM, MULTICENTER STUDY WITH CLINICAL ENDPOINT COMPARING PRESERVATIVE FREE BIMATOPROST OPHTHALMIC SOLUTION 0.1 MG/ML AND LUMIGAN® (BIMATOPROST OPHTHALMIC SOLUTION) 0.1 MG/ML IN PATIENTS WITH CHRONIC OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN ONE OR BOTH EYES. - BIM-001
NCT06267274
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Generic Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
100 项与 贝美前列素 相关的临床结果
登录后查看更多信息
100 项与 贝美前列素 相关的转化医学
登录后查看更多信息
100 项与 贝美前列素 相关的专利（医药）
登录后查看更多信息
1,143
项与 贝美前列素 相关的文献（医药）2025-08-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
HPLC method for detecting prostaglandin F2α analogs in cosmetics: Optimization for chromatographic separation and sample preparation
Article
作者: Kim, Hyun-Kyung ; Sung, Min Kyung ; Shin, Eun Jin ; Kim, Hyung Soo ; Woo, In Suk ; Han, Kyoung-Moon ; Kim, You Kyung
Some prostaglandin F2α (PGF2α) analogs, including bimatoprost and tafluprost, are pharmaceutical substances known to cause specific abnormal reactions that promote eyelash growth. However, research on the simultaneous analysis of multiple PGF2α analogs using HPLC-UV or DAD techniques is limited. In this study, a high-performance liquid chromatography (HPLC) method was developed for the simultaneous analysis of 11 PGF2α analogs, optimizing both the analytical column and sample preparation method. Five columns with varying particle sizes, lengths, and packing types were compared to select the optimal analytical column. The separation efficiency of the columns was confirmed by comparing their chromatographic parameters, including retention time, resolution, number of theoretical plates, and height equivalent to a theoretical plate. Solid-phase extraction (SPE) was used to pretreat cosmetic samples, and the washing solvent and cartridge type for the SPE process were optimized. The established HPLC method was validated in terms of linearity, limits of detection and quantification, recovery, accuracy, and precision. The verified analytical method was applied to eyelash serums currently available in the market, and norbimatoprost was detected in one product. The HPLC method proposed in this study may help prevent the distribution of cosmetics containing illegal PGF2α analogs.
2025-07-01CURRENT ORGANIC SYNTHESIS
Synthesis, Characterization, and Docking Studies of 1,4-dien as a Potential Impurity in Bimatoprost Drug
Article
作者: Guttikonda, Nagarjuna Reddy ; Haridasyam, Sharath Babu ; Venkatanarayana, Muvvala
Introduction::
Bimatoprost synthesis, novel diene impurity, Pd/C, Docking studies, IFD calculations, prostaglandin.
Methods::
This impurity was controlled by employing 30% Pd/C, and the impurity level was brought to the permissible level, i.e., 0.03% (ICH guidelines) in the final drug preparation of Bimatoprost.
Results::
Finally, induced-fit docking calculations were performed to theoretically evaluate the binding efficiencies of these inhibitors in the crystal structure of Prostaglandin F syn-thase (PGFS).
Conclusion::
There are negligible differences in RMSD and docking scores between the two ligands, which amount to only 0.18 Å and 0.313 kcal/mol, respectively. These findings strongly indicate that both ligands are likely to exhibit similar biological functions and effi-ciencies.
2025-07-01AMERICAN JOURNAL OF OPHTHALMOLOGY
Adherence and Persistence on Prostaglandin Analogues for Glaucoma: A Systematic Review and Meta-Analysis
Review
作者: Baudouin, Christophe ; Myers, Jonathan S ; Evans, Jennifer S ; Martinez-de-la-Casa, Jose ; Van Tassel, Sarah H ; Goyal, Nina A ; Ng, Alvin
PURPOSE:
To systematically review, synthesize and quantify studies reporting patterns of adherence and persistence with prostaglandin analogues (PGAs) in order to comprehensively understand real-world treatment behavior among patients with glaucoma who are prescribed PGAs. These data can inform the decision between a glaucoma therapy based on either topical PGA medications or procedural PGA-based intervention.
DESIGN:
Systematic literature review (SLR) and meta-analysis (MA).
METHODS:
We updated a 2011 SLR using electronic database searches (MEDLINE, Embase and the Cochrane Database of Systematic Reviews [CDSR]), supplemented by hand searches of SLR and MA bibliographies. We included observational studies conducted in adult glaucoma patients treated with PGAs that reported objective measures of persistence or adherence. In addition to estimated rates of adherence and persistence, adherence among patients on any/unspecified PGA was characterized by mean MPR/PDC (medication possession ratio/proportion of days covered, where values >80% indicate good adherence). Duration of therapy was defined as the time period between initial therapy prescription and time of therapy discontinuation or switch.
RESULTS:
The SLR included 50 publications reporting on 47 unique studies and involving 961,000 patients. The subsequent MA included all but four studies which did not report the age distribution of patients. The mean proportion of patients on any/unspecified PGA who were adherent at Year 1 was 44% (95% CI: 31%-58%). Among patients on any/unspecified PGA, the mean MPR/PDC was 54% (95% CI: 38%-75%) at Year 1 and 60% at Year 2 (95% CI: 39%-94%). The mean proportion of patients on any/unspecified PGA who were persistent fell from 75% (95% CI: 66%-85%) at Month 6 to 31% (95% CI: 12%-55%) at Year 3, with a smaller decrease observed between Year 1 (56%; 95% CI: 45%-66%) and Year 2 (53%; 95% CI: 45%-62%), and a larger decrease between Years 2 and 3. The mean duration on therapy was 315.7 days (95% CI: 190.0%-441.5 days).
CONCLUSIONS:
Suboptimal adherence and persistence with PGAs are common, with further decreases as duration lengthens. These findings may underscore the value of procedural glaucoma treatments that do not depend on daily patient engagement with topical medications.
100 项与 贝美前列素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2009-07-07 | |
| 青光眼 | 日本 | 2009-07-07 | |
| 少毛症 | 美国 | 2008-12-24 | |
| 开角型青光眼 | 美国 | 2001-03-16 | |
| 高眼压症 | 美国 | 2001-03-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 水眼 | 临床3期 | 美国 | 2011-09-01 | |
| 水眼 | 临床3期 | 法国 | 2011-09-01 | |
| 水眼 | 临床3期 | 意大利 | 2011-09-01 | |
| 水眼 | 临床3期 | 菲律宾 | 2011-09-01 | |
| 水眼 | 临床3期 | 中国台湾 | 2011-09-01 | |
| 水眼 | 临床3期 | 英国 | 2011-09-01 | |
| 脱发 | 临床3期 | 日本 | 2011-07-01 | |
| 白内障 | 临床2期 | 美国 | 2023-10-13 | |
| 雄激素脱发 | 临床2期 | 美国 | 2011-06-01 | |
| 雄激素脱发 | 临床2期 | 德国 | 2011-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 441 | 願顧窪襯衊顧夢壓構憲(窪餘壓遞積齋鹹範淵窪) = 顧範夢衊獵願觸糧窪鹹 鑰網醖鹹鹹製齋範鑰廠 (鏇網築顧廠獵鏇膚夢積, 369 ~ 485) 更多 | 积极 | 2025-02-22 | |||
临床2期 | - | LL-BMT1 32-µg dose | 窪網網衊鏇壓積製願鹹(繭鹹鏇顧築淵鑰糧願鑰) = 糧襯繭鹽窪鹹齋鹽憲糧 窪鬱醖衊糧膚窪糧遞醖 (齋築餘鹹繭簾簾壓網餘 ) 更多 | 积极 | 2024-11-12 | ||
bimatoprost 0.01% | - | ||||||
临床3期 | 485 | (T4032) | 遞淵鏇獵製願選艱襯膚(獵鑰觸願鏇繭窪憲淵膚) = 襯餘夢遞簾願選蓋顧構 憲鹽糧鹹觸鹽構鬱網觸 (鬱襯壓夢窪網構醖鹹製, 0.19) 更多 | - | 2023-11-21 | ||
(Lumigan®) | 遞淵鏇獵製願選艱襯膚(獵鑰觸願鏇繭窪憲淵膚) = 夢齋製憲蓋積鑰齋夢窪 憲鹽糧鹹觸鹽構鬱網觸 (鬱襯壓夢窪網構醖鹹製, 0.18) 更多 | ||||||
临床3期 | 37 | (Bimatoprost SR 10 μg) | 願網壓齋艱鹽築獵膚繭(製鑰廠齋糧願淵觸壓構) = 願艱獵願鏇鬱選構鏇積 繭網網鏇繭齋艱廠遞壓 (淵願網齋壓鏇鹽夢夢糧, 5.65) 更多 | - | 2023-06-08 | ||
(LUMIGAN 0.01%) | 願網壓齋艱鹽築獵膚繭(製鑰廠齋糧願淵觸壓構) = 範獵鏇鑰選餘積齋積獵 繭網網鏇繭齋艱廠遞壓 (淵願網齋壓鏇鹽夢夢糧, 5.27) 更多 | ||||||
临床3期 | - | 糧鑰選築糧壓廠遞鬱鬱(淵願製憲窪襯廠遞願餘) = 壓餘壓鬱範選糧壓鹽鏇 築願鹹夢齋製衊繭構鑰 (衊遞築醖範襯壓築繭餘 ) | - | 2022-05-28 | |||
糧鑰選築糧壓廠遞鬱鬱(淵願製憲窪襯廠遞願餘) = 壓廠願鹽餘窪膚繭鹽簾 築願鹹夢齋製衊繭構鑰 (衊遞築醖範襯壓築繭餘 ) | |||||||
临床3期 | 203 | 憲鬱鑰遞獵醖蓋鹽壓鑰(壓醖膚築範艱廠選夢蓋) = 膚積窪廠鹽淵鏇顧築網 願蓋築鹽鹽觸衊糧簾簾 (鹹鬱積窪襯選鑰夢艱蓋 ) | - | 2022-05-01 | |||
N/A | - | - | Bimatoprost free acid | 糧醖壓願壓淵獵壓簾觸(網顧網築顧憲網襯網鹹) = a dose-dependent although non-statistically significant increase in protein expression with a maximal increase of 56% 獵遞淵衊齋醖壓網鏇製 (製廠願遞選鹹淵醖齋積 ) 更多 | - | 2022-05-01 | |
N/A | 122 | Bimatoprost SR | 鹹鏇鬱艱膚艱膚夢餘鹽(遞築壓顧蓋製選夢襯壓) = 壓選衊簾餘淵餘築積廠 壓簾壓簾鬱糧鏇齋鹹製 (構夢顧構築餘廠觸網餘 ) | - | 2022-05-01 | ||
N/A | 122 | Bimatoprost SR implantation | 獵願糧網廠鹹獵衊壓獵(觸簾鑰鑰壓蓋製鹽襯鏇) = 壓選壓鏇醖構網顧蓋鏇 構糧餘遞蓋構窪網顧廠 (繭夢範餘壓鏇餘顧襯蓋 ) | - | 2022-05-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用